《滬深兩市》上證重上3,200點水平 深成創板半日升3.7%-4.4% 地產及中藥及白酒股走高 寧德時代續強勢
內地昨日(16日)新增本土確診病例1,226例,本土無症狀感染者1,207例。人民銀行今日(17日)進行800億元人民幣(下同)7天期逆回購操作,單日淨投放700億元。人民幣兌美元中間價今上調394點。昨日國務院金融委會議強調內地資本市場穩定發展後,A股各指數爆升。上證深成承接上日升勢今早高開高走,上證重上3,200點水平,深成及創板升幅顯着。
上證高見3,254,半日升82點或2.6%,近高收報3,252點;深成指漲447點或3.7%,收報12,448點;創業板指數高見2,754,半日升115點或4.4%,近高收報2,750點,成交2,060億元。上證深成半日成交分別爲3,390億元及4,719億元。
中資金融股工行(601398.SH)平收。建行(601939.SH)升0.5%。
地產股走高,金科股份(000656.SZ)、金地集團(600383.SH)、保利發展(600048.SH)及萬科(000002.SZ)升3.7%-9.3%。
白酒股造好,龍頭股貴州茅臺(600519.SH)及五糧液(000858.SZ)分別升3.8%及3%。
多家中藥企業產品獲納入最新新型冠狀病毒肺炎診療方案,刺激一衆中藥概念股掀漲停潮,亞寶藥業(600351.SH)、盤龍藥藥(002864.SZ)、紅日藥業(300026.SZ)及精華製藥(002349.SZ)漲停。
比亞迪(002594.SZ)及寧德時代(300750.SZ)分別升4.1%及5.7%。(ta/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.